Salasani, Jahiba .
HRN: 22-82-13 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/04/2023
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
04/04/2023
04/11/2023
IV
1.5g
Q6hours
Presumptive PTB
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes